Skip to main content
. Author manuscript; available in PMC: 2011 Jan 15.
Published in final edited form as: J Immunol. 2009 Dec 7;184(2):725–735. doi: 10.4049/jimmunol.0902080

FIGURE 9.

FIGURE 9

Mutation of Cys113 of Bet v 1d abrogates dimerization and reverts Bet v 1d-specific immunological properties. A, Bet v 1a, Bet v 1d, and Bet v 1d[Cys113Ser] were loaded on a reducing or nonreducing SDS-PAGE. The asterisk marks dimeric Bet v 1d. B, Ag uptake by BMDCs. BMDCs were incubated with FITC-Bet v 1a, FITC-Bet v 1d, or FITC-Bet v 1d[Cys113Ser]. One representative FACS profile is shown. Statistical analysis is given as mean ± SD; values of p are indicated in graph (n = 6). C, Expression of activation markers by BMDCs. Cells were gated for CD11c expression and the amount of CD80 and MHC II surface expression was determined. The graph shows the percentage of CD80 and MHC II-expressing cells within the Bet v 1-FITC–positive BMDCs. Mean ± SD; values of p are indicated in graph (unpaired Student t test) n = 3. D, Specific Ab response in mice. Mice were immunized with either Bet v 1a (dark gray circles), Bet v 1d[Cys113Ser] (light gray circles) or Bet v 1d (○) and boosted 2 wk after primary immunization. Serum was taken at day 21, and specific IgG1 and IgE serum titers were determined (n = 7–10). Values are shown as arbitrary units in comparison with a pooled standard serum. Mean values are given as dash ± SD; values of p are indicated in graph (unpaired Student t test).